Definitive Contract HHSN272201700011C
Award Date
1/30/17
Potential Completion Date
8/31/21
Potential Value
$7M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Chrysalis Biotherapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Galveston, TX 77550, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
29
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a task order award under a broader Indefinite Delivery/Indefinite Quantity (IDIQ) contract with a ceiling value of $1,429,082.54. The prime contractor is Battelle Memorial Institute, a large non-profit research and development organization. The contracting agency is the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The task order is for $132,813 and has an ultimate completion date of April 17,...
This is a $6,150,127.06 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to BCN Biosciences LLC for the development of medical countermeasures to mitigate and/or treat radiation-induced lung injury after a radiological/nuclear incident. The contract has an ultimate completion date of April 30, 2019 and does not have a set-aside designation. Based on the major program code, this contract supports NIAID's efforts to develop...
This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Macrogenics, Inc., a for-profit manufacturer, for research and development services related to advanced development. The contract has a ceiling value of $56,058,625.93 and was awarded on September 29, 2006, with an ultimate completion date of September 28, 2011. The contract is not set-aside for any...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside designation....
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,728,096.00 cost-plus-fixed-fee definitive contract to Myelo Therapeutics GmbH, a for-profit limited liability company, for the development of MYELO001 as an orally applied medical countermeasure to treat hematopoietic acute radiation syndrome. This contract, which has a completion date of January 16, 2025, stems from a Broad Agency Announcement seeking proposals to develop safe and effective medical...
This is a $81,904,328.96 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to the University of Maryland, Baltimore (UMB) for radiation/nuclear medical countermeasure product development support services. The contract supports the development of medical countermeasures against radiation and nuclear threats, which aligns with NIAID's mission to conduct and support research to...
This is a federal contract award to Capital Biosciences, Inc. for "DRUGS AND BIOLOGICALS" with a Firm Fixed Price contract type and ceiling value of $10,000.00. The contract was awarded on December 29, 2011 by the National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the U.S. Department of Health and Human Services (HHS). The contract has an ultimate completion date of January 19, 2012 and was not set aside for any special programs. This appears to be a...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to Battelle Memorial Institute, a large nonprofit research and development organization. The contract is for the "Evaluation of Clinical Samples from Influenza Clinical Trials" and has a ceiling value of $5,744,120.00. The contract is a Delivery Order under the NIAID's existing contract vehicle, with a Cost Plus Fixed Fee pricing structure. The contract...
<p>The federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University System of Maryland as the prime contractor. The 7-year contract, valued at $844,451.00, is for "BIOMEDICAL (BASIC)" services and does not have a set-aside designation. The contract was awarded on July 15, 2003, with a completion date of July 13, 2010. The contract type is a Definitive Contract with a Cost No Fee pricing type.</p>